Cassidy James 4

4 · SpringWorks Therapeutics, Inc. · Filed Jan 9, 2023

Form 4

Period: 2023-01-05

Chief Medical Officer

Transactions

Award
Stock Option (Right to Buy)
2023-01-05+70,000→ 70,000 total
Exercise: $27.64Exp: 2033-01-05→ Common Stock (70,000 underlying)
Award
Common Stock
2023-01-05+22,663→ 48,493 total
Tax Payment
Common Stock
2023-01-06$27.52/sh−1,263$34,758→ 47,230 total
Award
Stock Option (Right to Buy)
2023-01-05+65,000→ 65,000 total
Exercise: $27.64Exp: 2033-01-05→ Common Stock (65,000 underlying)

Footnotes (4)

[F1]This transaction represents a grant of restricted stock units ("RSUs"). The RSUs shall vest as follows: thirty three percent (33%) to vest on January 5, 2024, another thirty three percent (33%) to vest on January 5, 2025 and the remaining thirty four percent (34%) to vest on January 5, 2026, such that the restricted stock awards are fully vested on January 5, 2026.
[F2]Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person.
[F3]This option shall vest in 48 equal monthly installments subject to continued service to the Issuer by the Reporting Person.
[F4]Twenty-five percent (25%) of this option shall vest and become exercisable on January 5, 2024, with the remaining seventy-five percent (75%) to vest in thirty-six (36) equal monthly installments thereafter subject to continued service to the Issuer by the Reporting Person.

Documents

1 file